Guangzhou Xinji Pharmaceutical Co., Ltd. renewed its draft prospectus in September 2026, signaling its intent to list on the main board of the Hong Kong Stock Exchange, with Guotai Junan International serving as the sole sponsor. The company has yet to bring a self-developed product to market, and its financial performance continues to be weighed down by substantial losses.
Between 2024 and the first five months of 2026, Xinji Pharma recorded cumulative net losses totaling RMB 456 million. During this period, annual losses have widened each year, reflecting the heavy investment required to advance its clinical-stage pipeline and expand operational capabilities.
Currently, the company generates revenue exclusively from two segments: contract research organization (CRO) services and marketing authorization holder (MAH) services. However, both business lines experienced a sharp downturn in early 2026, with combined revenue falling 22.4% year-over-year for the first five months. This contraction highlights the volatility of service-based income and the challenges of building a sustainable revenue stream without proprietary product sales.
Xinji Pharma’s two lead drug candidates, DHMP and XJN010, remain in clinical trials. DHMP is being developed for the treatment of certain central nervous system disorders, while XJN010 targets chronic inflammatory conditions. Both programs are at early-to-mid stage clinical development, and the company expects that neither will receive regulatory approval in China before 2028 at the earliest. This timeline underscores the lengthy and uncertain path from clinical trials to market authorization.
Research and development spending has more than doubled over the past three years, climbing steadily as the company pushes its pipeline forward. In the first five months of 2026 alone, R&D expenses reached RMB 18.961 million, nearly matching the full-year figures from just a few years ago. The escalating burn rate reflects not only the costs of running clinical trials but also investments in regulatory affairs, manufacturing scale-up, and intellectual property protection.
The IPO proceeds, if completed, are expected to fund the ongoing clinical development of DHMP and XJN010, support preparatory work for commercialization, and augment working capital. However, analysts note that the company faces significant hurdles, including the absence of approved products, a shrinking service revenue base, and the capital-intensive nature of drug development with no guaranteed timeline for profitability.
Xinji Pharma’s pursuit of a Hong Kong listing comes amid a broader wave of Chinese biotech firms seeking international capital markets. For investors, the company’s story hinges on the successful advancement of its two key assets and its ability to eventually transition from a service-dependent business model to a product-driven pharmaceutical company. Until then, the financial losses are expected to persist, with any meaningful revenue inflection unlikely before the end of the decade.
